Targeting tumor suppressor inactivation to treat osteosarcoma
Leveraging Tumor Suppressor Inactivation for Osteosarcoma Therapy
This study is looking at new ways to treat osteosarcoma, a serious bone cancer in kids, by focusing on a protein called Skp2 that helps cancer cells grow; the goal is to find treatments that could help kids with this condition live longer and healthier lives.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-10881775 on NIH RePORTER |
What this research studies
This research focuses on developing new therapies for osteosarcoma, a common and aggressive bone cancer in children. The approach involves targeting a specific protein, Skp2, which plays a crucial role in cancer cell growth and metastasis. By understanding how Skp2 contributes to the disease, the researchers aim to create molecular-based treatments that could improve survival rates for patients with osteosarcoma. The study will analyze the effects of inhibiting Skp2 on tumor progression and patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are pediatric patients diagnosed with osteosarcoma who have limited treatment options due to relapsed or metastatic disease.
Not a fit: Patients with osteosarcoma who are in the early stages of the disease and have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for osteosarcoma, potentially improving survival rates and quality of life for affected patients.
How similar studies have performed: Other research has shown promising results in targeting similar oncogenic pathways in various cancers, suggesting that this approach could be effective for osteosarcoma as well.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Hoang, Bang H — Albert Einstein College of Medicine
- Study coordinator: Hoang, Bang H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.